Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Study of QEL-005 in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc) and in Patients With Difficult to Treat Rheumatoid Arthritis (D2TRA).

NCT07473154 is registered in ClinicalTrials.gov with Quell Therapeutics Limited as lead sponsor.

NCT NCT07473154
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07473154 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Study of QEL-005 in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc) and in Patients With Difficult to Treat Rheumatoid Arthritis (D2TRA).
Lead sponsor
Quell Therapeutics Limited
Phase
Phase 1/2
Overall status
Recruiting
Start date
April 10, 2026
Completion date
August 31, 2028
Enrollment
16 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

autoimmune rheumatologic disease, diffuse cutaneous systemic sclerosis, rheumatoid arthritis (ra), systemic sclerosis (ssc)